CTE Sessions at EANM’11

EANM’11 – CTE Session IV

October 17, 2011, 16:30 – 18:00
Radionuclides in Therapy in Neuroendocrinal Tumours

Moderators: T. Eriksen (Oslo)


Speakers
extended
abstract
L. Bodei (Milan):
The Use of PRRT in Neuroendocrine Tumours
J. Buscombe (Cambridge):
The Use of 131I-MIBG in Neuroendocrine Tumours
F. Sudbrock (Koeln):
131I-MIBG – Dosimetry and Measurement for Dosimetric Purposes


Educational objectives:

Upon completion of this session the attendee will be able to:

  1. Describe the use of PRRT in therapy of neuroendocrine tumours.
  2. Describe the use of MIBG in therapy of neuroendocrine tumours.
  3. Understand the difference between the use of PRRT and MIBG.
  4. Understand the limitations in use of PRRT and MIBG for adults and children.


Summary:

Neuroendocrine tumours (NET) are relatively rare tumours with relative high mortality (40%) and poor survival for children. Treatment should be individualized according to the tumour type. Somatostatin analogues 90Y-DOTATOC, 177LU-DOTOTATE (PRRT) and 131I-MIBG have been used for several years. In this session we will hear about how somatostatin analogues and 131I-MIBG are used as medical treatment. Will therapy using PRRT receptor together with other treatment improve the survival of patients with neuroendocrine tumours?


Key Words:

Neuroendocrine Tumours (NET), 131I-MIBG, 90Y DATATOC, 177LU-DOTATATE, Therapy, PRRT (Peptide Receptor Radionuclide Therapy)

Back to top